Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Recruiting 4Withdrawn 1Unknown 1Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 10Urinary Bladder Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1First-line Treatment 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1

Interventions

Fluorouracil 34Leucovorin 31Oxaliplatin 25Irinotecan 19Capecitabine 13Folfox protocol 12Cetuximab 12Chemotherapy, Adjuvant 11Bevacizumab 9Neoadjuvant Therapy 8Drug Therapy 8XELOX 7Laparoscopy 7Endoscopic Mucosal Resection 5Colonoscopy 5Surgical Procedures, Operative 4Gemcitabine 4Tegafur 3Radiotherapy 3Propofol 3Preoperative Exercise 3Panitumumab 3Fentanyl 3Curcumin 3Colectomy 3Aspirin 3raltitrexed 2Surveys and Questionnaires 2Sodium Chloride 2Simvastatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Colonic Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT03992456 2024-05-21

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Academic and Community Cancer Research United

Phase 2 Unknown
12 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡